Literature DB >> 10417057

Long term hematopoietic damage after chemotherapy and cytokine.

R V Gardner1.   

Abstract

Cancer chemotherapy causes severe damage to hematopoietic stem cells in both experimental animals and humans. While all levels of differentiation may be impacted, the most pivotal target of damage is the most primitive hematopoietic stem cell, PHSC. This cell not only suffers defective repopulating activity but also is quantitatively depleted. The causes of this damage are not clear. Severe possible explanations for this damage are discussed. They include: ineffective stromal support of stem cell function and reproduction; residual DNA damage preventing replication; accelerated cycling; and decreased responsiveness to normal physiologic growth stimuli. Efforts at chemoprotection, including manipulation of glutathione or aldehyde dehydrogenase levels, cytostatic peptides, immunomodulatory chemicals and cytokines are detailed. In particular, concern has been raised regarding potential deleterious consequences of combined chemotherapy-cytokine use, but substantiation of the cited data is warranted.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10417057     DOI: 10.2741/A479

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  9 in total

1.  Induction of blood-circulating bile acids supports recovery from myelosuppressive chemotherapy.

Authors:  Valgardur Sigurdsson; Youichi Haga; Hajime Takei; Els Mansell; Chizuko Okamatsu-Haga; Mitsuyoshi Suzuki; Visnja Radulovic; Mark van der Garde; Shuhei Koide; Svetlana Soboleva; Mats Gåfvels; Hiroshi Nittono; Akira Ohara; Kenichi Miharada
Journal:  Blood Adv       Date:  2020-05-12

2.  Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion.

Authors:  Shenghui He; Patrick J Roberts; Jessica A Sorrentino; John E Bisi; Hannah Storrie-White; Renger G Tiessen; Karenann M Makhuli; William A Wargin; Henko Tadema; Ewoud-Jan van Hoogdalem; Jay C Strum; Rajesh Malik; Norman E Sharpless
Journal:  Sci Transl Med       Date:  2017-04-26       Impact factor: 17.956

3.  Significant impairment in immune recovery after cancer treatment.

Authors:  Duck-Hee Kang; Michael T Weaver; Na-Jin Park; Barbara Smith; Traci McArdle; John Carpenter
Journal:  Nurs Res       Date:  2009 Mar-Apr       Impact factor: 2.381

4.  Baseline immune biomarkers as predictors of MBSR(BC) treatment success in off-treatment breast cancer patients.

Authors:  Richard R Reich; Cecile A Lengacher; Kevin E Kip; Steven C Shivers; Michael J Schell; Melissa M Shelton; Raymond H Widen; Catherine Newton; Michelle K Barta; Carly L Paterson; Jerrica R Farias; Charles E Cox; Thomas W Klein
Journal:  Biol Res Nurs       Date:  2014-01-28       Impact factor: 2.522

5.  Simultaneous detection of circulating immunological parameters and tumor biomarkers in early stage breast cancer patients during adjuvant chemotherapy.

Authors:  B Rovati; S Mariucci; S Delfanti; D Grasso; C Tinelli; C Torre; M De Amici; P Pedrazzoli
Journal:  Cell Oncol (Dordr)       Date:  2016-01-14       Impact factor: 6.730

Review 6.  Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows.

Authors:  Patrick J Roberts; Vishnu Kumarasamy; Agnieszka K Witkiewicz; Erik S Knudsen
Journal:  Mol Cancer Ther       Date:  2020-06-16       Impact factor: 6.261

7.  Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models.

Authors:  Lewis H Bender; Franco Abbate; Ian B Walters
Journal:  Int J Mol Sci       Date:  2020-06-24       Impact factor: 5.923

8.  A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19.

Authors:  Emre Yekedüz; Güngör Utkan; Yüksel Ürün
Journal:  Eur J Cancer       Date:  2020-10-06       Impact factor: 9.162

9.  The impact of anti-tumor approaches on the outcomes of cancer patients with COVID-19: a meta-analysis based on 52 cohorts incorporating 9231 participants.

Authors:  Qing Wu; Shuimei Luo; Xianhe Xie
Journal:  BMC Cancer       Date:  2022-03-04       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.